Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2014

01-09-2014 | Research Article

Nin one binding protein expression as a prognostic marker in prostate carcinoma

Authors: G. Liu, D. Shen, L. Jiao, Y. Sun

Published in: Clinical and Translational Oncology | Issue 9/2014

Login to get access

Abstract

Background

To investigate the prognostic value of expression levels of nin one binding protein (Nob1) in prostate carcinoma.

Methods

Nob1 protein levels were evaluated by Western blot in samples from 40 prostate carcinomas and matched adjacent non-neoplastic prostate tissues. Nob1 expression was also assessed by immunohistochemistry in samples from 300 prostate carcinoma and matched adjacent non-neoplastic prostate tissues, as well as 20 benign prostatic hyperplasia samples. The findings were compared with clinical and pathologic parameters and patient outcome.

Results

Nob1 protein analysis showed significant differences between the prostate carcinomas and control groups tested. Immunohistochemical analysis showed that Nob1 positivity was higher in prostate carcinoma than that in paired adjacent non-cancerous tissues (58 vs 7 %, P < 0.001). Nob1 positivity was significantly associated with high Gleason scores and metastasis in patients. Nob1 expression was significantly associated with shorter biochemical recurrence-free survival (BCRFS). Multivariate analysis revealed that Nob1 is an independent marker for BCRFS.

Conclusions

These findings provide evidence that Nob1 is an indicator of poor prognosis in prostate carcinoma.
Literature
1.
Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013;2013:560857.PubMedCentralPubMedCrossRef
2.
Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Semin Oncol. 2013;40:322–36.PubMedCrossRef
3.
Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008;13:1634–45.PubMedCrossRef
4.
5.
Zhang Y, Ni J, Zhou G, Yuan J, Ren W, Shan Y, Tang W, Yu L, Zhao S. Cloning, expression and characterization of the human NOB1 gene. Mol Biol Rep. 2005;32:185–9.PubMedCrossRef
6.
Hong L, Piao Y, Han Y, Wang J, Zhang X, Du Y, et al. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Mol Cancer Ther. 2005;4:1936–42.PubMedCrossRef
7.
Granneman S, Nandineni MR, Baserga SJ. The putative NTPase Fap7 mediates cytoplasmic 20S pre-rRNA processing through a direct interaction with Rps14. Mol Cell Biol. 2005;25:10352–64.PubMedCentralPubMedCrossRef
8.
Lin Y, Peng S, Yu H, Teng H, Cui M. RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol. 2012;29:311–7.PubMedCrossRef
9.
Ghadersohi A, Sharma S, Zhang S, Azrak RG, Wilding GE, Manjili MH, et al. Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate. 2011;71:1178–88.PubMedCentralPubMedCrossRef
10.
Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011;9:43.PubMedCentralPubMedCrossRef
11.
Li XY, Luo QF, Li J, Wei CK, Kong XJ, Zhang JF, et al. Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma. Int J Clin Exp Pathol. 2013;6:2137–44.PubMedCentralPubMed
12.
Kluge R, Giesen K, Bahrenberg G, Plum L, Ortlepp JR, Joost HG. Quantitative trait loci for obesity and insulin resistance (Nob1, Nob2) and their interaction with the leptin receptor allele (LeprA720T/T1044I) in New Zealand obese mice. Diabetologia. 2000;43:1565–72.PubMedCrossRef
13.
Che JP, Li W, Yan Y, Liu M, Wang GC, Li QY, Yang B, Yao XD, Zheng JH. Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma. Int J Clin Exp Pathol. 2013;6:2300–11.PubMedCentralPubMed
Metadata
Title
Nin one binding protein expression as a prognostic marker in prostate carcinoma
Authors
G. Liu
D. Shen
L. Jiao
Y. Sun
Publication date
01-09-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 9/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1158-x

Other articles of this Issue 9/2014

Clinical and Translational Oncology 9/2014 Go to the issue

Research Article

Iron deficiency in patients with solid tumours: prevalence and management in clinical practice

Research Article

Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model

Research Article

Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma

Research Article

Exclusive radiotherapy for gliomatosis cerebri: long-term follow-up at a single institution

Research Article

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

Research Article

Effects of common polymorphisms rs2910164 in miR-146a and rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits